BioAdvance

Founded in 2002, BioAdvance is a venture capital firm based in Radnor, Pennsylvania. The firm seeks to invest in health-tech firms including therapeutics, medical devices, diagnostics, research tools and healthcare IT sectors located in the mid-Atlantic region.



BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund.



Since its first investments, BioAdvance has committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement.

Investment

BioAdvance's investments include Novira Therapeutics, Immunome, Halo Labs, Leversense, Niiki Pharma, Solaris Therapeutics, Galleon Pharmaceuticals, Cool-Bio and CarePartners Plus.



Their exited investments include Advaxis, Relmada Therapeutics, Novira Therapeutics, NuPathe, HealthQx, Ceptaris Therapeutics, Avid Radiopharmaceuticals, Acuity Pharmaceuticals, Protez Pharmaceuticals and Immune Control.